COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee
- Creators
- Turner, Paul J.
- Ansotegui, Ignacio J.
- Campbell, Dianne E.
- Cardona, Victoria
- Ebisawa, Motohiro
- El-Gamal, Yehia
- Fineman, Stanley
- Geller, Mario
- Gonzalez-Estrada, Alexei
- Greenberger, Paul Allen
- Leung, Agnes S. Y.
- Levin, Michael E.
- Muraro, Antonella
- Borges, Mario Sanchez
- Senna, Gianenrico
- Tanno, Luciana K.
- Thong, Bernard Yu-Hor
- Worm, Margitta
- WAO Anaphylaxis Committee
Abstract
Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the United Kingdom and United States. More recent data imply an incidence of anaphylaxis closer to 1:200,000 doses with respect to the Pfizer-BioNTech vaccine. In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.
Other
original_citation: Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, Fineman S, Geller M, Gonzalez-Estrada A, Greenberger PA, Leung ASY, Levin ME, Muraro A, Borges MS, Senna G, Tanno LK, Thong BYH, Worm M, Comm WAOA. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organization Journal. 2021;14(2):10.
Acknowledgements
We thank Drs Sophie Farooque and Alessia Baseggio Conrado (London) for reviewing a draft of this manuscript.
Files
Name | Size | Download all |
---|---|---|
md5:e22b08bbd1567b944402ca635e8a7a5d
|
1.0 MB | Preview Download |
Additional details
- PMID
- 33558825
- Created
-
2021-02When the item was originally created.